Latest J&J-partnered Legend Biotech data spotlight continued high response rate but 10 patient deaths
Legend Biotech has has a good three years ever since the then-little known biotech unveiled a round of BCMA CAR-T data at ASCO. It helped net them a partnership with J&J and, more recently, one of biotech history’s biggest IPOs.
Now, the Nanjing-based biotech unveiled their largest set of data for the therapy, showing interim results from a pivotal US study conducted with J&J. The data affirmed the drug’s now well-documented efficacy, with a 94% response rate and a 55% complete response rate, but it also revealed that, out of 97 patients in the study, 10 died.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.